The right diagnosis,
right away,
at the right price.

We are the creators of Genomtec ID, a mobile platform for genetic diagnosis in the point of patient care.
We have marketed the first SARS-CoV-2 rapid diagnostic kits including the world’s first genetic diagnostic test for the detection of SARS-CoV-2 directly from a saliva sample.

News

2022.04.29

Genomtec signs distribution agreement for Genomtec®ID in Europe

Genomtec has signed an exclusive distribution agreement in Greece for its flagship Genomtec®ID genetic testing platform and the Respiratory Panel 5-plex test. Genomtec’s commercial partner Atropos Ltd., is a specialist distributor of molecular biology solutions with an established market position in Greece. Atropos will start the distribution following the regulatory approval of the Genomtec®ID platform […]

2022.02.14

Genomtec begins comparative testing phase of Genomtec®ID

Genomtec has started the comparative testing phase of Genomtec®ID, a mobile platform for genetic diagnostics and the Respiratory Panel (RP) 5-plex assay. The results obtained in this clinical study will be the basis for the CE-IVD registration of Genomtec®ID in the European Union planned for the middle of this year. This multi-center study will be […]

2022.01.20

European Patent Office grants Genomtec with new Patent

Genomtec has received a patent from the European Patent Organization (EPO) for the Genomtec®ID technology and device invented by Genomtec SA.  The invention under new patent protection includes Genomtec®ID, the Company’s key technology related to a proprietary non-contact heating and temperature sensing system developed for point-of-care testing (POCT) and other applications. This is the first […]

Awards